Clinical relevance of TRKA expression on neuroblastoma: comparison with N-NYC amplification and CD44 expression
1997

TRKA Expression in Neuroblastoma

Sample size: 108 publication Evidence: moderate

Author Information

Author(s): V Combaret, N Gross, C Lasset, K Balmas, R Bouvier, D Frappaz, C Beretta-Brognara, T Philip, MC Favrot, J-L Coil

Hypothesis

Does TRKA expression correlate with clinical outcomes in neuroblastoma?

Conclusion

TRKA expression is a strong prognostic factor in neuroblastoma, particularly when combined with N-MYC or CD44 assessment.

Supporting Evidence

  • 74 out of 108 neuroblastomas expressed TRKA protein, correlating with favorable clinical outcomes.
  • Event-free survival at 3 years was 81% in TRKA-positive patients compared to 27% in TRKA-negative patients.
  • TRKA expression was significantly associated with low stage and absence of N-MYC amplification.

Takeaway

This study found that a protein called TRKA can help doctors predict how well children with neuroblastoma will do, especially when looking at other factors like N-MYC and CD44.

Methodology

TRKA expression was evaluated on 122 untreated neuroblastomas using immunohistochemistry, and the prognostic value was analyzed through univariate and multivariate analyses.

Potential Biases

Selection of patients was based on the availability of sufficient tumor tissue, which may introduce bias.

Limitations

The study's sample included a disproportionate occurrence of low stage neuroblastomas, which may affect the generalizability of the results.

Participant Demographics

Patients were untreated children diagnosed with neuroblastoma, with a mean follow-up time of 35 months.

Statistical Information

P-Value

4 x 10-5

Confidence Interval

[0;35]

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication